LIBOI, Elio Maria
 Distribuzione geografica
Continente #
NA - Nord America 1.470
EU - Europa 1.117
AS - Asia 314
AF - Africa 1
OC - Oceania 1
SA - Sud America 1
Totale 2.904
Nazione #
US - Stati Uniti d'America 1.467
GB - Regno Unito 477
CN - Cina 291
SE - Svezia 130
IE - Irlanda 114
FI - Finlandia 89
IT - Italia 89
FR - Francia 79
DE - Germania 72
UA - Ucraina 30
BE - Belgio 28
TR - Turchia 17
NL - Olanda 5
CA - Canada 3
IN - India 2
RU - Federazione Russa 2
AR - Argentina 1
DK - Danimarca 1
IL - Israele 1
IQ - Iraq 1
IR - Iran 1
JP - Giappone 1
NZ - Nuova Zelanda 1
RS - Serbia 1
SL - Sierra Leone 1
Totale 2.904
Città #
Southend 404
Jacksonville 272
Chandler 270
Woodbridge 223
Ann Arbor 118
Dublin 114
Ashburn 78
Houston 67
Wilmington 58
Verona 43
Jinan 42
Beijing 38
Lawrence 35
Princeton 35
Philadelphia 29
Brussels 28
Nanjing 25
Helsinki 24
Shenyang 24
Falls Church 21
Boardman 20
Hebei 18
Tianjin 17
Taiyuan 13
Nanchang 12
Sindelfingen 10
Zhengzhou 10
Fuzhou 9
Milan 9
Auburn Hills 8
Changsha 8
Haikou 7
Jiaxing 7
Ningbo 7
Taizhou 7
Lanzhou 5
Seattle 5
Hangzhou 4
Redmond 4
Washington 4
Blaricum 3
Dearborn 3
Detroit 3
Toronto 3
Ypsilanti 3
Augusta 2
Düsseldorf 2
Fairfield 2
Groningen 2
Guangzhou 2
Hanover 2
Latina 2
Mestre 2
Mira 2
New York 2
Norwalk 2
Paris 2
Rome 2
San Diego 2
San Francisco 2
Tappahannock 2
Andover 1
Auckland 1
Belgrade 1
Buenos Aires 1
Cambridge 1
Changle 1
Charlotte 1
Copenhagen 1
Evanston 1
Frankfurt am Main 1
Freetown 1
Kunming 1
Los Angeles 1
Mountain View 1
Novokuznetsk 1
Puxian 1
Reston 1
Rotherham 1
Simi Valley 1
Stockholm 1
Xiangfen 1
Yuanping 1
Zanjan 1
Totale 2.202
Nome #
C-fos proto-oncogene transient transcription is negatively affected in the Ela4-2 transformed rat cell line 147
K650M-FGFR3 mutant causes cytoskeleton alteration and paxillin hyperphosphorylation through c-Src and FAK activation. 113
K644E/M FGFR3 mutants activate Erk1/2 from the endoplasmic reticulum through FRS2a and PLCgamma-independent pathways 107
TGF beta induces a sustained c-fos expression associated with stimulation or inhibition of cell growth in EL2 or NIH 3T3 fibroblasts 104
Positive selection of apoptosis-resistant cells correlates with activation of dominant-negative STAT5 101
Proliferative response and oncogene expression induced by epidermal growth factor in EL2 rat fibroblasts 99
Epidermal growth factor induces, in the EL alpha 4-2 cell line, herpes simplex virus-1 alpha 4 gene transcription in the absence of the viral trans-activator VP16 97
Identification by monoclonal antibodies of a new epitope in the glycoprotein complex of Sindbis virus 97
Inhibition of polyoma gene expression in transformed mouse cells by hypermethylation 92
Role of SADDAN-FGFR3 mutant in cytoskeletal disorganization from the endoplasmic reticulum 92
Abnormal signaling by FGFR3-K650M mutant associated with SADDAN disease targets paxillin causing cytoskeleton disorganization. 91
Altered growth factor sensitivity in EL2 rat fibroblasts: influence of this biological characteristic on cell growth 90
SADDAN-FGFR3 signalling involves paxillin phosphorylation and causes cytoskeleton disorganization. 89
Activation of the JAK/STAT pathway leads to proliferation of ST14A central nervous system progenitor cells 88
The EL2 rat fibroblasts line: differential effects of growth factors (EGF, PDGF, FGF, TPA and TGF beta) on cell proliferation and c-fos expression 86
Stimulation of DNA synthesis by Interferon and Transforming Growth Factor b in EL2 rat fibroblasts 86
Enhanced expression of interleukin-3 and granulocyte-macrophage colony-stimulating factor receptor subunits in murine hematopoietic cells stimulated with hematopoietic growth factors 85
Role of the c-fos gene expression on the mitogenic response in EL2 rat fibroblasts 85
SADDAN-FGFR3 causes cytoskeleton disorganization and paxillin hyperphosphorylation by Src 83
The thanatophoric dysplasia type II mutation hampers complete maturation of fibroblast growth factor receptor 3 (FGFR3), which activates signal transducer and activator of transcription 1 (STAT1) from the endoplasmic reticulum. 82
New rat cell line that is highly susceptible to transformation by several oncogenes 81
The kinase activity of fibroblast growth factor receptor 3 with activation loop mutations affects receptor trafficking and signaling 80
Regulation of cell proliferation by inducible-secreted proteins in growth factor-treated EL2 rat fibroblasts 78
Naturally occurring C-terminally truncated STAT5 is a negative regulator of Human Immunodeficiency Virus-type1 expression. 76
Erythropoietin receptor signals both proliferation and erythroid-specific differentiation 75
Ultrastructural and biochemical evidence that the L929 cell retrovirus lacks the env gene translation product 75
Cell adaptation to activated FGFR3 includes Sprouty4 up regulation to inhibit the receptor-mediated ERKs activation from the endoplasmic reticulum 75
Mutant FGFR3 associated with SADDAN disease causes cytoskeleton disorganization through PLCγ1/Src-mediated paxillin hyperphosphorylation 75
Secreted proteins induced by epidermal growth factor and transforming growth factor beta in EL2 rat fibroblasts. Role in the mitogenic response 70
Upon dendritic cell activation chemokines and chemokine receptor expression are rapidly regulated for recruitment and maintenance of dendritic cells at the inflammatory site 68
Heterogeneity of signal transducer and activator of transcription-5 binding sites in the long terminal repeats of distinct HIV-1 subtypes 67
Negative regulation of HIV.1 transcription by a heterodimeric NK-KappaB1 p50 and C-terminally truncated STAT5 complex 54
Transient dimerization and interaction with ergic-53 occur in the Fibroblast Growth Factor Receptor 3 early secretory pathway 53
Synergism between thymosin alpha one and epidermal Growth Factor in the stimulation of rat fibroblast cell proliferation: cellular and molecular aspects 52
Regulation of succinate dehydrogenase and role of succinate in cancer 36
Totale 2.929
Categoria #
all - tutte 7.068
article - articoli 6.005
book - libri 0
conference - conferenze 1.063
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.136


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201922 0 0 0 0 0 0 0 0 11 4 5 2
2019/2020364 46 0 3 34 33 60 24 34 17 44 15 54
2020/2021389 35 55 16 61 47 45 2 31 29 2 51 15
2021/2022290 24 75 0 7 21 19 7 16 13 13 24 71
2022/2023717 46 79 70 121 60 166 13 35 83 3 18 23
2023/2024219 10 27 41 29 52 12 27 20 1 0 0 0
Totale 2.929